CJC-1295 GHRH-R Research: Pharmacology Profile and Cell Model Studies

CJC-1295 GHRH-R Research: Pharmacology Profile and Cell Model Studies

CJC-1295 is a research compound studied in cell-based assay formats for its GHRH-R (class B GPCR) Gs/cAMP/PKA signalling with DAC albumin-binding modification. Published in vitro research characterises its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions.

Receptor Pharmacology and Mechanism of Action

CJC-1295 acts as a selective agonist at the growth hormone-releasing hormone receptor (GHRH-R), a class B G protein-coupled receptor. The compound exhibits enhanced receptor binding characteristics compared to native GHRH through structural modifications that improve stability and binding kinetics. In vitro receptor binding studies demonstrate CJC-1295's high affinity interaction with GHRH-R, with binding constants indicating strong receptor engagement across multiple cell model systems.

The peptide's mechanism involves activation of the Gs protein pathway, leading to adenylyl cyclase stimulation and subsequent cyclic adenosine monophosphate (cAMP) elevation. This cascade activates protein kinase A (PKA), which phosphorylates downstream transcription factors including CREB (cAMP response element-binding protein). Laboratory studies using fluorescence-based cAMP assays consistently demonstrate dose-dependent increases in intracellular cAMP levels following CJC-1295 treatment in GHRH-R-expressing cell lines.

Drug Affinity Complex (DAC) Modification

The drug affinity complex (DAC) component represents a critical pharmacological feature of CJC-1295. This modification involves conjugation with a maleimidopropionic acid linker that facilitates albumin binding through covalent interaction with cysteine residues. In vitro albumin binding studies reveal high-affinity interactions, with association constants indicating strong protein conjugation under physiological conditions.

Cell-based pharmacokinetic modelling demonstrates that DAC modification significantly alters the compound's distribution and availability profiles in culture medium containing albumin. Binding kinetics studies show rapid albumin association followed by slower dissociation rates, creating a reservoir effect that maintains sustained receptor activation over extended timeframes in continuous perfusion cell culture systems.

Cell Model Systems and Assay Development

Primary Cell Models

Research applications utilize various cell model systems expressing endogenous GHRH-R. Primary pituitary adenocyte cultures serve as physiologically relevant models for investigating CJC-1295's receptor pharmacology. These systems demonstrate robust cAMP responses to CJC-1295 stimulation, with EC50 values typically ranging in the nanomolar concentration range across multiple independent cell preparations.

Immortalized cell lines transfected with human GHRH-R provide standardized platforms for reproducible pharmacological characterization. HEK293 and CHO cell systems expressing recombinant GHRH-R enable detailed receptor binding studies, competition assays, and downstream signalling pathway analysis under controlled experimental conditions.

Signalling Pathway Analysis

Advanced cell-based assays reveal CJC-1295's effects on multiple downstream signalling cascades beyond the primary Gs/cAMP pathway. Calcium mobilization studies in certain cell models indicate potential cross-talk with calcium-dependent signalling mechanisms. Phosphoproteomic analysis demonstrates PKA-mediated phosphorylation of numerous substrate proteins involved in transcriptional regulation and metabolic enzyme activity.

Real-time PCR analysis of GHRH-R-expressing cell cultures treated with CJC-1295 reveals time-dependent changes in gene expression profiles. Transcriptional targets include immediate early genes and factors involved in growth hormone synthesis and secretion pathways, demonstrating functional coupling between receptor activation and downstream cellular responses.

Comparative Receptor Pharmacology

Structure-activity relationship studies comparing CJC-1295 with native GHRH and other analogues reveal distinct pharmacological profiles. Receptor binding competition assays demonstrate CJC-1295's enhanced binding affinity, with improved receptor residence time compared to unmodified peptides. Functional selectivity studies indicate preserved efficacy at GHRH-R while maintaining selectivity over related class B GPCRs.

Enzyme kinetics analysis of adenylyl cyclase activation shows CJC-1295 produces sustained enzymatic activity compared to transient responses observed with native GHRH. This prolonged activation profile correlates with extended cAMP elevation and downstream pathway engagement in cell-based functional assays.

Research Summary

In vitro pharmacological characterization establishes CJC-1295 as a potent GHRH-R agonist with unique albumin-binding properties through DAC modification. Cell model studies demonstrate nanomolar binding affinity, robust Gs/cAMP/PKA pathway activation, and sustained receptor engagement. The compound's pharmacological profile in various cell-based assay systems supports its utility as a research tool for investigating GHRH-R signalling mechanisms and downstream cellular responses in controlled laboratory environments.

All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.

Hexarelin

TB-500

Epithalon

Ipamorelin

Tirzepatide

CJC-1295 DAC

PT-141

Semaglutide

Selank

BPC-157

Sermorelin

Melanotan 2

IGF LR3

Tesamorelin

AICAR

IGF-DES

GHRP 2

Albuterol

Tamoxifen

Letrozole

Clomiphene

Tadalafil

Clenbuterol

Anastrozole

Finasteride

Exemestane

Sildenafil

Yohimbine

Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows

Already a customer? Sign In

Create Account

All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.

ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.

Sarms

Stacks

Research Liquids

Albuterol 5MG/ML | 30ML with dropper

Anastrozole 1.5MG/ML | 30ML with dropper

Clomiphene 50MG/ML | 30ML with dropper

Finasteride 5MG/ML | 30ML with dropper

Letrozole 3.5 MG/ML | 30ML with dropper

LiquiCia 30MG/ML | 30ML with dropper

LiquiCia T50 50MG/ML | 30ML with dropper

LiquiClen 200MCG/ML | 30ML with dropper

Liquistane / Exemestane 25MG/ML | 30ML with dropper

LiquiTamo 20MG/ML | 30ML with dropper

LiquiVia 25MG/ML | 30 ML with dropper

T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper

Toremifene Citrate 60MG/ML | 30ML with dropper

Yohimbine HCL 10MG/ML | 30ML with dropper

Research Peptides

Aicar 50MG

BPC-157 + TB-500 Blend 2mg ea/ 4MG

BPC-157 5MG

CJC-1295 + DAC 2MG

CJC-1295 | No DAC 2MG

Epithalon 10MG

Frag Premium 176-191 5MG

GHK-CU Copper Peptide 50MG

GHRP-2 5MG

GHRP-6 5MG

Hexarelin 5MG

IGF-1 DES 1MG

IGF-1 LR3 1MG

Ipamorelin 5MG

Melanotan 2 10MG

NAD+ 500MG

PT-141 / Bremelanotide 10MG

GLP-1/GIP/GCG (RT)

Selank 5MG

GLP1 (SM)

Sermorelin 5MG

TB-500 5MG

GIP/GLP-1 (TZ)

PDE5 Inhibitors

GLP-1

Diluents

Bacteriostatic Water 10ML